08Jan
The New Exclusive European Licensee of Cenobamate: Angelini Pharma Acquires Emerging Swiss Biotech Company Arvelle Therapeutics
The Italian pharmaceutical company Angelini Pharma announced on January 4, 2021, that it will acquire emerging Swiss biotech company Arvelle Therapeutics for a total aggregate valuation of up to $960 million. Angelini Pharma will pay Arvelle Therapeutics $610 million following the European Medicines Agency’s (“EMA”) approval of the epilepsy drug cenobamate, sold under the brand name Xcopri®. Arvelle will also receive another $350 million if cenobamate reaches certain revenue targets....
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
While the impact of the COVID-19 pandemic on the real estate development industry remains unclear, s...
Read More >
The NRC will soon issue in the Federal Register a proposed rulemaking to amend the drug testing requ...
Read More >
What You Should Know - The National Labor Relations Board has proposed three policy changes to its ...
Read More >
In a few weeks, the Connecticut Supreme Court will begin it’s next session. As I looked at the cal...
Read More >
On May 23, 2019, the U.S. House of Representatives passed the Setting Every Community Up for Retirem...
Read More >
This week, the U.S. Department of Labor (DOL) published its highly anticipated Final Rule, which all...
Read More >